NAD+ and Aging: What the Science Actually Says in 2026

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every living cell. It's essential for energy metabolism, DNA repair, gene expression regulation, and cellular communication. Without adequate NAD+, your cells cannot function properly — mitochondria produce less ATP, DNA damage accumulates faster, and inflammatory pathways activate.

NAD+ is also the fuel for sirtuins — a family of seven proteins (SIRT1-7) that regulate aging, inflammation, and stress resistance. Sirtuins need NAD+ to function. When NAD+ levels drop, sirtuin activity drops with them, accelerating virtually every hallmark of aging.

Plasma NAD+ drops approximately 60% from early adulthood to late adulthood. This decline is not random — it's driven by three specific NAD+-consuming enzymes:

PARPs (Poly ADP-Ribose Polymerases) — activated by DNA damage, PARPs consume NAD+ to repair broken DNA strands. As we age and accumulate more DNA damage, PARPs consume more NAD+.

CD38 — an enzyme expressed primarily by immune cells that breaks down NAD+ during inflammatory responses. Chronic low-grade inflammation ("inflammaging") means CD38 is constantly active, draining NAD+.

SARM1 — activated by neuronal stress, SARM1 destroys NAD+ in axons, contributing to neurodegeneration.

The result is a vicious cycle: aging increases the demand for NAD+ while simultaneously reducing its supply. The 2025 "NAD World 3.0" framework, published in npj Aging, added a new dimension to this understanding: inter-tissue NAD+ communication. Different organs communicate their NAD+ status to each other, creating system-wide effects when any single tissue becomes depleted.

The primary strategy for restoring NAD+ is oral supplementation with precursors — molecules the body converts into NAD+.

Nicotinamide Riboside (NR) and Nicotinamide Mononucleotide (NMN) are the two most studied precursors. Both have shown robust NAD+ replenishment in preclinical models, with downstream effects including enhanced mitochondrial function, improved stem cell activity, accelerated tissue repair, and muscle regeneration. Animal studies have shown lifespan extensions of up to 30% in invertebrates.

The clinical reality in 2026 is more nuanced. Multiple human studies have confirmed that NR and NMN supplementation does raise blood NAD+ levels. But large-scale, long-term human trials demonstrating clear healthspan or lifespan benefits remain scarce. The preclinical evidence is compelling; the human evidence is still catching up.

Upcoming trials are focusing on Alzheimer's disease, Parkinson's, obesity, and Type 2 diabetes — conditions where NAD+ depletion is particularly well-documented.

NAD+ optimization is woven into several ExtraLife protocols. The Longevity Protocol (Epithalon + TA-1, $279/month) targets the telomere and cellular senescence side of aging. Epithalon — a synthetic pineal peptide studied for over 30 years — has shown dose-dependent telomere length extension in both cancer and normal human cell lines, as confirmed by a 2025 study in Biogerontology.

For Concierge and ExtraLife Protocol members, NAD+ assessment is part of comprehensive biomarker tracking. The goal isn't just supplementation — it's understanding your individual NAD+ trajectory and addressing the specific drivers of decline (inflammation, DNA damage, neuronal stress) through personalized protocols.

This is the ExtraLife approach: don't just throw a supplement at the problem. Understand the mechanism, measure the biomarkers, and personalize the intervention.